Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Dextroamphetamine. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC6A2 known ✓ | P23975 | 4/20 | 0.95 |
| ▸ | SLC6A3 known ✓ | Q01959 | 2/20 | 0.95 |
| ▸ | TAAR1 | Q96RJ0 | 4/20 | 0.95 |
| ▸ | SLC6A4 | P31645 | 3/20 | 0.95 |
| ▸ | MAOA | P21397 | 1/20 | 0.95 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.95 |
| ▸ | CYP2A6 | P11509 | 1/20 | 0.95 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.95 |
| ▸ | ADORA1 | P30542 | 1/20 | 0.95 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.64 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.61 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Levamfetamine SCHEMBL4070216 | 1.00 | SLC6A2 (0.95) | SLC6A2TAAR1SLC6A4SLC6A3MAOA | |
| Levamfetamine SCHEMBL573666 | 1.00 | SLC6A2 (0.95) | SLC6A2TAAR1SLC6A4SLC6A3MAOA | |
| Amphetamine SCHEMBL27581784 | 1.00 | SLC6A2 (0.95) | SLC6A2TAAR1SLC6A4SLC6A3MAOA | |
| Amphetamine SCHEMBL4070210 | 1.00 | SLC6A2 (0.95) | SLC6A2TAAR1SLC6A4SLC6A3MAOA | |
| Amphetamine SCHEMBL573665 | 1.00 | SLC6A2 (0.95) | SLC6A2TAAR1SLC6A4SLC6A3MAOA | |
| Dextroamphetamine SCHEMBL9114306 | 1.00 | SLC6A2 (0.95) | SLC6A2TAAR1SLC6A4SLC6A3MAOA | |
| Amphetamine SCHEMBL15094242 | 0.97 | SLC6A2 (1.00) | SLC6A2TAAR1SLC6A4SLC6A3MAOA | |
| Amphetamine SCHEMBL1560962 | 0.97 | SLC6A2 (1.00) | SLC6A2TAAR1SLC6A4SLC6A3MAOA | |
| Levamfetamine SCHEMBL9673275 | 0.97 | SLC6A2 (1.00) | SLC6A2TAAR1SLC6A4SLC6A3MAOA | |
| Dextroamphetamine SCHEMBL8859 | 0.97 | SLC6A2 (1.00) | SLC6A2TAAR1SLC6A4SLC6A3MAOA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 85 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250206698-A1 | Process for Making Lisdexamfetamine Dimesylate | Pharmapotheca A, Inc. | 2025-06-26 | — | — | US | claimed |
| US-20100104624-A1 | COMBINATION THERAPY USING PHOSPHODIESTERASE INHIBITORS | COMGENRX, INC. | 2010-04-29 | — | — | US | claimed |
| WO-2009152344-A2 | COMBINATION THERAPY USING PHOSPHODIESTERASE INHIBITORS | COMGENRX, INC. (US) | 2009-12-17 | — | — | WO | claimed |
| US-20030194439-A1 | Pharmaceutical dosage form for pulsatile delivery of methylphenidate | MIDHA KAMAL K (BM) | 2003-10-16 | — | — | US | claimed |
| US-6555136-B2 | First, second and optionally third dosage units, with each dosage unit having a different drug release profile. | PHARMAQUEST, LTD. (BM) | 2003-04-29 | — | — | US | claimed |
| US-20020058061-A1 | Pharmaceutical dosage form for pulsatile delivery of methylphenidate | MIDHA KAMAL K (CA) | 2002-05-16 | — | — | US | claimed |
| US-6217904-B1 | MIXTURES; ADMINISTERING IN CYCLES | PHARMAQUEST LTD. (BM) | 2001-04-17 | — | — | US | claimed |
| US-3968245-A | Sympathomimetic topical and percutaneous administration with halogenated promoters | ALZA CORPORATION (US) | 1976-07-06 | — | — | US | claimed |
| WO-2026047284-A1 | METHOD FOR THE PREPARATION OF LISDEXAMFETAMINE | FERMION OY (FI) | 2026-03-05 | — | — | WO | disclosed |
| US-20250206698-A1 | Process for Making Lisdexamfetamine Dimesylate | Pharmapotheca A, Inc. | 2025-06-26 | — | — | US | disclosed |
| US-20250090554-A1 | A METHOD OF TREATING DEPRESSION BY IMMUNE MODULATION | MYND LIFE SCIENCES INC (CA) | 2025-03-20 | — | — | US | disclosed |
| CN-112004520-B | Modified release pharmaceutical powder compositions comprising a gastric raft formation system with triggered pulsatile drug release | 特瑞斯制药公司 | 2024-08-23 | — | — | CN | disclosed |
| CN-117326953-A | Preparation method of lisdexamphetamine dimesylate intermediate | 四川科瑞德制药股份有限公司 | 2024-01-02 | — | — | CN | disclosed |
| CN-116057060-B | Spiro-containing derivative, preparation method and application thereof | 上海枢境生物科技有限公司 | 2023-08-29 | — | — | CN | disclosed |
| EP-0585310-A4 | CROSSTALK INHIBITORS AND THEIR USES. | BIOSITE DIAGNOSTICS INC (US) | 1995-06-14 | — | — | EP | disclosed |
| US-5326708-A | Drug abuse | UNITED STATES DRUG TESTING LABORATORIES, INC. | 1994-07-05 | — | — | US | disclosed |
| EP-0585310-A1 | CROSSTALK INHIBITORS AND THEIR USES | BIOSITE DIAGNOSTICS INC. (US) | 1994-03-09 | — | — | EP | disclosed |
| WO-1992018868-A1 | CROSSTALK INHIBITORS AND THEIR USES | BIOSITE DIAGNOSTICS INCORPORATED (US) | 1992-10-29 | — | — | WO | disclosed |
| EP-0108218-A2 | Constant release rate solid oral dosage formulation of pharmaceutical compounds having a high degree of water solubility | VEREX LABORATORIES, INC. (US) | 1984-05-16 | — | — | EP | disclosed |
| US-3968245-A | Sympathomimetic topical and percutaneous administration with halogenated promoters | ALZA CORPORATION (US) | 1976-07-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250206698-A1 | Process for Making Lisdexamfetamine Dimesylate | COMT, MGAM, ADH5 | SLC6A2 48/4885SLC6A3 10/4885TAAR1 448/4885 |
| US-20030194439-A1 | Pharmaceutical dosage form for pulsatile delivery of methylphenidate | SLC18A1, SLC6A3, CRH | SLC6A2 10/4885SLC6A3 2/4885TAAR1 554/4885 |
| US-20020058061-A1 | Pharmaceutical dosage form for pulsatile delivery of methylphenidate | SLC18A1, SLC6A3, CRH | SLC6A2 10/4885SLC6A3 2/4885TAAR1 554/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.